Peter Willinger

• 
  www.lionbioscience.com/company/management/index_eng.htm - [Cached Version]
  Published on: 3/10/2007    Last Visited: 3/10/2007  

  Peter WillingerPeter Willinger is Chief Financial Officer of LION bioscience AG.He joined the company in November 1998 as Director Controlling and served as Vice President Global Finance & Operations since October 2001.After he received his BA degree in business economics at the Mannheim University, he worked as a controller for Rudolf Wild GmbH & Co KG in Heidelberg for eight years.

• 
  www.lionbioscience.com/press/release/latest_releases/li - [Cached Version]
  Published on: 4/21/2006    Last Visited: 3/10/2007  

  „In fact, this new operating business requires expenses, but offers a large opportunity for the new company," explained Peter Willinger, CEO of LION. „A consolidation of the new company will happen at the end of the second quarter at the earliest.Momentarily, we are in the integration phase, in which the legal prerequisites for the realisation of the transaction will be set up," stated Willinger.
  
  For the key figures of Q1 and a complete report of LION's Q1 fiscal year 2006/07 results, please click on the link on the right.
  
  For further information please contact:
  
  Peter WillingerChief Executive Officer

• 
  www.lionbioscience.com/investors/corporate_governance/e - [Cached Version]
  Published on: 3/10/2007    Last Visited: 3/10/2007  

  Peter WillingerPeter Willinger ist Finanzvorstand der LION bioscience AG.Er kam im November 1998 als Director Controlling zu LION und war seit Oktober 2001 Vice President Global Finance & Operations.Nachdem er an der Berufsakademie Mannheim seinen Abschluss als Diplom-Betriebswirt erwarb, arbeitete er acht Jahre als Controller bei der Rudolf Wild GmbH & Co KG/Heidelberg.

• 
  www.lionbioscience.com/e5/e45342/e47529/e60642/index_en - [Cached Version]
  Published on: 11/17/2004    Last Visited: 3/10/2007  

  Peter Willinger, who is head of the finance department since 1998, was appointed Chief Financial Officer (CFO).
  ...
  Peter Willinger joined LION in November 1998 as Director Controlling and served as Vice President Global Finance & Operations since October 2001.After he received his BA degree in business economics at the Mannheim University, he worked as a controller for Rudolf Wild GmbH & Co KG/Heidelberg for eight years.

• 
  www.lionbioscience.com/e5/e45342/e60675/e60995/index_en - [Cached Version]
  Published on: 4/21/2006    Last Visited: 3/10/2007  

  All obligations resulting from the bioinformatics business have been assigned to the buyer, therefore, we can now focus on the future business, based on a clean and strengthened position," said Peter Willinger, CFO of LION bioscience.
  
  The bioinformatics unit, comprising the 100%-owned subsidiaries, LION Bioscience Ltd., Cambridge, UK and LBAV, Inc, Cambridge, MA, USA, will be taken over by BioWisdom Ltd., a company specializing in providing healthcare intelligence to business leaders in the pharmaceutical and biotechnical industry.The sales price consists of a fixed and variable payment.The latter is based on the business development over the next 12 months.
  
  In connection with the sale of the bioinformatics business, the planned reduction of the Management Board, approved by the shareholders' meeting in March 2005, has taken place, with Dr. Thure Etzold resigning as CEO as of April 4, 2006.Peter Willinger will be the sole member of the Management Board.
  
  "The disposal of the bioinformatics business was a primary precondition for the future strategy of LION and its position in the market," said Peter Willinger."LION is currently reviewing potential promising options within the life science business.We are confident, that we will be able to provide more specific updates with this regards to our position shortly," added Willinger.
  
  For further information, please contact:
  
  LION bioscience AGPeter WillingerChief Financial OfficerTel: +49 (0) 6221-4038 293Email: peter.willinger@lionbioscience.com

• 
  www.lionbioscience.com/press/release/latest_releases/li - [Cached Version]
  Published on: 4/21/2006    Last Visited: 3/10/2007  

  At the same time we were able to achieve a positive result of the operating bioinformatics activities for the first time", said Peter Willinger, CFO of LION bioscience AG."We would be happy if we were able to achieve a faster conclusion to this process, but for us a good result is as important as the time factor", said Willinger.
  ...
  Peter Willinger Chief Financial Officer

• 
  www.lionbioscience.com/e5/e45342/e60675/e61032/index_en - [Cached Version]
  Published on: 4/21/2006    Last Visited: 3/10/2007  

  Peter WillingerChief Executive OfficerTel: +49 (0) 6221-4038 293Email: peter.willinger@lionbioscience.com

• 
  www.lionbioscience.com/e5/e45342/e60675/e60856/index_en - [Cached Version]
  Published on: 4/21/2006    Last Visited: 3/10/2007  

  We are controlling our costs well and there is only a small need to use our cash reserves", said Peter Willinger, LION's CFO."The restructuring activities have been quite hard, but the result shows they were necessary and reasonable.We are pleased that the way we adapted has brought us quickly to our target and we will continue working hard to lead the company into sustainable profitability."
  
  The company is also focused on the sales process of its bioinformatics unit."We expect to announce a successful sale within the next few weeks", said Willinger.
  ...
  Peter WillingerChief Financial Officer

• 
  www.lionbioscience.com/press/release/latest_releases/di - [Cached Version]
  Published on: 4/21/2006    Last Visited: 3/10/2007  

  The new company, whose name will be decided on at LION's annual general meeting this autumn, will be headed by the two management board members Alfred Bach (Axaron) and Peter Willinger (LION).
  ...
  Peter Willinger sees a great opportunity for the new company: "We are convinced of the mutual concept and are delighted to form this new company in a highly attractive market with Dietmar Hopp, BASF and Axaron, and to generate sustainable added value for our shareholders."

• 
  www.lionbioscience.com/e4/e15343/e15441/e61007/index_en - [Cached Version]
  Published on: 4/4/2006    Last Visited: 3/10/2007  

  Peter WillingerChief Financial OfficerTel: +49 (0) 6221-4038 293Email: peter.willinger@lionbioscience.com

Page:  1 2 3 4